Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Cabotegravir-Rilpivirine Long Acting (CAB-RPV LA) Implementation Strategies Among High-Risk Populations

NCT04973254 is registered in ClinicalTrials.gov with Boston Medical Center as lead sponsor.

NCT NCT04973254
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04973254 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Cabotegravir-Rilpivirine Long Acting (CAB-RPV LA) Implementation Strategies Among High-Risk Populations
Lead sponsor
Boston Medical Center
Phase
Not applicable
Overall status
Completed
Start date
February 23, 2022
Completion date
March 28, 2023
Enrollment
25 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

hiv infections